Apogee Therapeutics (APGE) Research & Development (2022 - 2026)

Apogee Therapeutics (APGE) has reported Research & Development for 5 consecutive years, with $60.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Research & Development rose 31.11% year-over-year to $60.8 million; the TTM figure through Mar 2026 stood at $229.1 million (up 23.5% YoY), while the FY2025 annual figure was $214.7 million, up 27.91% from the prior year.
• Research & Development climbed to $60.8 million in Q1 2026 per APGE's latest filing, from $58.4 million in the prior quarter.
• Across five years, Research & Development topped out at $60.8 million in Q1 2026 and bottomed at $1.4 million in Q2 2022.
• Historically, Research & Development has averaged $33.5 million across 5 years, with a median of $31.1 million in 2023.
• Annual changes were most pronounced in 2023 — Research & Development jumped 863.12% — and 2025, when it declined 2.96%.
• Apogee Therapeutics' Research & Development stood at $12.2 million in 2022, then surged by 137.17% to $29.0 million in 2023, then soared by 108.02% to $60.2 million in 2024, then slipped by 2.96% to $58.4 million in 2025, then climbed by 4.06% to $60.8 million in 2026.
• Business Quant data shows APGE's Research & Development at $60.8 million in Q1 2026, $58.4 million in Q4 2025, and $54.2 million in Q3 2025.